|
|
 Previous Article | Table of Contents | Next Article 
Productive infection by B19 parvovirus of human erythroid bone marrow cells
in vitro
K Ozawa, G Kurtzman and N Young
B19 parvovirus, the cause of fifth disease and transient aplastic crisis,
has been successfully propagated in suspension cultures of human erythroid
bone marrow cells obtained from patients with sickle cell disease and
stimulated by erythropoietin. B19 inoculation in vitro resulted in a marked
decline in identifiable erythroid cells over seven to nine days of
incubation. Characteristic giant early erythroid cells were seen on
Wright's-Giemsa stain of infected cultures. By in situ hybridization, 30%
to 40% of erythroblasts were infected at 48 hours; a similar proportion of
cells showed B19 capsid protein by immunofluorescence. B19 DNA was present
in erythroblasts but not in the leukocyte fraction of bone marrow. B19
replication, as determined by Southern analysis, and B19 encapsidation, as
determined by sensitivity of isolated cell fractions to DNase I, were
restricted to the nuclei. B19 DNA was detectable in the nuclei from
infected cultures beginning at 18 hours and in the supernatant at 32 hours;
B19 genome copy number was estimated at about 25,000 to 30,000/infected
cell at 48 hours. Recovery of virus depended on the multiplicity of
infection (moi); at low moi, approximately 200x input virus was recovered
from total cultures and 50x from the culture supernatants. Virus released
into the supernatant was as infectious or more infectious than virus
obtained from sera of infected patients. Human erythroid bone marrow
culture represents a safe in vitro system for the elucidation of the
cellular and molecular biology of the pathogenic B19 parvovirus.
Volume 70,
Issue 2,
pp. 384-391,
08/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Pillet, S. Fichelson, F. Morinet, N. S. Young, N. Zhi, and S. Wong
Human B19 Erythrovirus In Vitro Replication: What's New?
J. Virol.,
September 1, 2008;
82(17):
8951 - 8953.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wong, N. Zhi, C. Filippone, K. Keyvanfar, S. Kajigaya, K. E. Brown, and N. S. Young
Ex Vivo-Generated CD36+ Erythroid Progenitors Are Highly Permissive to Human Parvovirus B19 Replication
J. Virol.,
March 1, 2008;
82(5):
2470 - 2476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Waldman and J. B. Kopp
Parvovirus B19 and the Kidney
Clin. J. Am. Soc. Nephrol.,
July 1, 2007;
2(Supplement_1):
S47 - S56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. W. Cooling, D. S. Zhang, S. J. Naides, and T. A. W. Koerner
Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts
Blood,
January 15, 2003;
101(2):
711 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Sedger, S. Hou, S. R. Osvath, M. B. Glaccum, J. J. Peschon, N. van Rooijen, and L. Hyland
Bone Marrow B Cell Apoptosis During In Vivo Influenza Virus Infection Requires TNF-{alpha} and Lymphotoxin-{alpha}
J. Immunol.,
December 1, 2002;
169(11):
6193 - 6201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Heegaard and K. E. Brown
Human Parvovirus B19
Clin. Microbiol. Rev.,
July 1, 2002;
15(3):
485 - 505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Morita, K. Tada, H. Chisaka, H. Asao, H. Sato, N. Yaegashi, and K. Sugamura
Human Parvovirus B19 Induces Cell Cycle Arrest at G2 Phase with Accumulation of Mitotic Cyclins
J. Virol.,
August 15, 2001;
75(16):
7555 - 7563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Weigel-Kelley, M. C. Yoder, and A. Srivastava
Recombinant Human Parvovirus B19 Vectors: Erythrocyte P Antigen Is Necessary but Not Sufficient for Successful Transduction of Human Hematopoietic Cells
J. Virol.,
May 1, 2001;
75(9):
4110 - 4116.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. C. Segovia, J. M. Gallego, J. A. Bueren, and J. M. Almendral
Severe Leukopenia and Dysregulated Erythropoiesis in SCID Mice Persistently Infected with the Parvovirus Minute Virus of Mice
J. Virol.,
March 1, 1999;
73(3):
1774 - 1784.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Ponnazhagan, K. A. Weigel, S. P. Raikwar, P. Mukherjee, M. C. Yoder, and A. Srivastava
Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes
J. Virol.,
June 1, 1998;
72(6):
5224 - 5230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Frickhofen, J. L. Abkowitz, M. Safford, J. M. Berry, J. Antunez-de-Mayolo, A. Astrow, R. Cohen, I. Halperin, L. King, D. Mintzer, et al.
Persistent B19 Parvovirus Infection in Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-1): A Treatable Cause of Anemia in AIDS
Ann Intern Med,
December 15, 1990;
113(12):
926 - 933.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Risks Associated With Human Parvovirus B19 Infection
Arch Dermatol,
April 1, 1989;
125(4):
475 - 480.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Risks Associated With Human Parvovirus B19 Infection
JAMA,
March 17, 1989;
261(11):
1555 - 1563.
[PDF]
|
|
|
|
|
